The incorporation of IL-6R blockade into the treatment regimen renders patients with pancreatic cancer with high baseline TGFβ-specific immunity unresponsive to immune checkpoint inhibitors and radiotherapy. Here, TGFB1 is linked to pancreatic neoplasm.